PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Feng, Chenchen ^a   Sun, Yang ^b   Ding, Guanxiong ^a   Wu, Zhong ^a   Jiang, Haowen ^a   Wang, Lujia ^a   Ding, Qiang ^a   Wen, Hui ^a  

^a FUDAN UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE LYSINE METHYLTRANSFERASE; MORPHOLINE DERIVATIVE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PYRIMIDINONE DERIVATIVE; SET2 PROTEIN, HUMAN; TGX 221; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL TRANSFORMATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG RESISTANCE, NEOPLASM; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; MORPHOLINES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; PYRIMIDINONES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84927928063     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09465     Document Type: Article

References (34)

1. Linehan, W. M. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 22, 2089-100 (2012).
2. George, D. J. & Kaelin, W. G., Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349, 419-21 (2003).
3. Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44, 17-9 (2012).
4. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-3 (2010).
5. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-42 (2011).
6. Hwang, C. & Heath, E. I. The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma. J Clin Oncol 32, 729-34 (2014).
7. Stein, A. et al. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol 64, 994-1002 (2013).
8. Albiges, L. et al. A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. Eur Urol 67, 100-10 (2015).
9. Motzer, R. J., Hutson, T. E., McCann, L., Deen, K. & Choueiri, T. K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370, 1769-70 (2014).
10. Chong, C. R. & Janne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19, 1389-400 (2013).
11. Shinojima, T. et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 28, 529-36 (2007).
12. Zhu, X. et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 46, 287-93 (2014).
13. Rahma, O. E. et al. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med 8, 8 (2010).
14. Choi, Y. J. et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol 45, 1674-81 (2014).
15. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 19, 3259-67 (2013).
16. Wang, S. S. et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci U S A 111, 16538-43 (2014).
17. Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-9 (2013).
18. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45, 860-7 (2013).
19. Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7, 85-90 (1994).
20. Schraml, P. et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196, 186-93 (2002).
21. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91, 9700-4 (1994).
22. Gronhoj Larsen, C. et al. Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review. Br J Cancer 110, 1587-94 (2014).
23. Murali, R., Soslow, R. A. & Weigelt, B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 15, e268-78 (2014).
24. Shepherd, P. R. & Denny, W. A. Beta-testing of PI3-kinase inhibitors: is beta better? Cancer Discov 2, 393-4 (2012).
25. Ni, J. et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov 2, 425-33 (2012).
26. El-Mokadem, I. et al. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery. Br J Cancer 111, 1381-90 (2014).
27. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883-92 (2012).
28. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1 (2013).
29. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-4 (2012).
30. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-5 (2012).
31. Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41, D955-61 (2013).
32. Feng, C. et al. Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness. Folia Biol (Praha) 57, 242-247 (2011).
33. Feng, C.-C. et al. Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urologic Oncology: Seminars and Original Investigations 31, 241-246 (2013).
34. Ding, G. et al. Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition. PLOS ONE 8, e77400 (2013).